Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis

Tien Y Wong, Mkaya Mwamburi, Ronald Klein, Michael Larsen, Harry Flynn, Marisol Hernandez-Medina, Gayatri Ranganathan, Barbara Wirostko, Andreas Pleil, Paul Mitchell, Tien Y Wong, Mkaya Mwamburi, Ronald Klein, Michael Larsen, Harry Flynn, Marisol Hernandez-Medina, Gayatri Ranganathan, Barbara Wirostko, Andreas Pleil, Paul Mitchell

Abstract

Objective: This meta-analysis reviews rates of progression of diabetic retinopathy to proliferative diabetic retinopathy (PDR) and/or severe visual loss (SVL) and temporal trends.

Research design and methods: This systematic literature review and meta-analysis of prospective studies assesses progression of retinopathy among diabetic patients without treatment for retinopathy at baseline. Studies published between 1975 to February 2008 were identified. Outcomes of interest were rates of progression to PDR and/or SVL. Pooled baseline characteristics and outcome measures were summarized using weighted averages of counts and means. Baseline characteristics and outcomes were compared between two periods: 1975-1985 and 1986-2008.

Results: A total of 28 studies comprising 27,120 diabetic patients (mean age 49.8 years) were included. After 4 years, pooled incidence rates for PDR and SVL were 11.0 and 7.2%, respectively. Rates were lower among participants in 1986-2008 than in 1975-1985. After 10 years, similar patterns were observed. Participants in 1986-2008 studies had lower proportions of PDR and non-PDR at all time points than participants in 1975-1985 studies.

Conclusions: Since 1985, diabetic patients have lower rates of progression to PDR and SVL. These findings may reflect an increased awareness of retinopathy risk factors; earlier identification and initiation of care for patients with retinopathy; and improved medical management of glucose, blood pressure, and serum lipids. Differences in baseline characteristics, particularly in the prevalence and severity of retinopathy, could also have contributed to these temporal differences.

Figures

Figure 1
Figure 1
Selection of studies for systematic review.

References

    1. Congdon NG, Friedman DS, Lietman T: Important causes of visual impairment in the world today. JAMA 2003; 290: 2057– 2060
    1. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF: Lifetime risk for diabetes mellitus in the United States. JAMA 2003; 290: 1884– 1890
    1. Ciulla TA, Amador AG, Zinman B: Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003; 26: 2653– 2664
    1. Marshall SM, Flyvbjerg A: Prevention and early detection of vascular complications of diabetes. BMJ 2006; 333: 475– 480
    1. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J: Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994; 330: 15– 18
    1. Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N, Binder C, Parving HH: Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003; 26: 1258– 1264
    1. Nishimura R, Dorman JS, Bosnyak Z, Tajima N, Becker DJ, Orchard TJ: Diabetes Epidemiology Research International Mortality Study, Allegheny County Registry. Incidence of ESRD and survival after renal replacement therapy in patients with type 1 diabetes: a report from the Allegheny County Registry. Am J Kidney Dis 2003; 42: 117– 124
    1. Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J: Linköping Diabetes Complications Study. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of type 1 diabetes: the Linköping Diabetes Complications Study. Diabetologia 2004; 47: 1266– 1272
    1. James M, Turner DA, Broadbent DM, Vora J, Harding SP: Cost effectiveness analysis of screening for sight threatening diabetic eye disease. BMJ 2000; 320: 1627– 1631
    1. Mohamed Q, Gillies MC, Wong TY: Management of diabetic retinopathy: a systematic review. JAMA 2007; 298: 902– 916
    1. Ferris FL, 3rd: How effective are treatments for diabetic retinopathy? JAMA 1993; 269: 1290– 1291
    1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977– 986
    1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837– 853
    1. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH: Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997; 314: 783– 788
    1. PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 2007; 125: 318– 324
    1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 1989; 107: 244– 249
    1. Klein R, Moss SE, Klein BE, Davis MD, DeMets DL: The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. Ophthalmology 1989; 96: 1501– 1510
    1. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985; 103: 1796– 1806
    1. The Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report no. 4. Int Ophthalmol Clin 1987; 27: 265– 272
    1. Effects of aspirin treatment on diabetic retinopathy. ETDRSreport number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98( Suppl. 5): 757– 765
    1. Early photocoagulation for diabetic retinopathy. ETDRSreport number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98( Suppl. 5): 766– 785
    1. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRSreport number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98( Suppl. 5): 823– 833
    1. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N: DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008; 372: 1385– 1393
    1. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK: DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372: 1394– 1402
    1. Fleiss J: Statistical Methods for Rates and Proportions. Hoboken, New Jersey, John Wiley & Sons, 1973
    1. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719– 748
    1. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177– 188
    1. Hedges L, Olkin I: Statistical Methods for Meta-Analysis. 1985: 230– 257, Academic Press, Orlando, FL.
    1. Aldington SJ, Kohner EM, Meuer S, Klein R, Sjølie AK: Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia 1995; 38: 437– 444
    1. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII: the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes (Letter). Ophthalmology 1998; 105: 1799– 1800
    1. Gómez-Ulla F, Fernandez MI, Gonzalez F, Rey P, Rodriguez M, Rodriguez-Cid MJ, Casanueva FF, Tome MA, Garcia-Tobio J, Gude F: Digital retinal images and teleophthalmology for detecting and grading diabetic retinopathy (Letter). Diabetes Care 2002; 25: 1384– 1389
    1. Csaky Karl G, Richman Elaine A, Ferris Frederick LI: Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium: investigative ophthalmology & visual science 2008; 49: 479– 489
    1. Hove MN, Kristensen JK, Lauritzen T, Bek T: The relationships between risk factors and the distribution of retinopathy lesions in type 2 diabetes. Acta Ophthalmologica Scandinavica 2006; 84: 619– 623
    1. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998; 105: 1801– 1815

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi